Biography
Dr. Blayney's research interests include breast cancer, febrile neutropenia mitigation, and the use big data to improve cancer care quality and value. He has over 90 scientific publications. Dr. Blayney has served on the Food and Drug Administration's Oncologic Drugs Advisory Committee, and is Founding Editor-in-Chief and Editor-in-Chief Emeritus of ASCO's Journal of Oncology Practice. He has a degree in electrical engineering from Stanford, is a graduate of the University of California, San Diego School of Medicine, and received post graduate training at UCSD and at the National Cancer Institute in Bethesda, Maryland.
He is married, and has three grown daughters, one of whom is also a physician.
Professional Summary
Education & Certifications
- Medical Education: University of California San Diego School of Medicine (1977) CA
- Residency: UCSD Internal Medicine Residency (1980) CA
- Fellowship: National Cancer Institute - Center Cancer Research (1983) MD
- Board Certification: American Board of Internal Medicine, Medical Oncology (1983)
- Board Certification: American Board of Internal Medicine, Internal Medicine (1980)
- Fellowship, Medicine Branch, National Cancer Institute, Bethesda, Maryland (1983)
- Fellowship, Environmental Epidemiology Branch, National Cancer Institute, Bethesda, Maryland (1983)
- Resident, University of California Hospitals, San Diego (1980)
- M.D., University of California, San Diego (1977)
- B.S.E.E., Stanford University (1972)
Honors & Awards
- Best Doctors in America, . (2007 - current)
- Fellow, American College of Physicians (1991)
- Fellow, American Society of Clinical Oncology (2007)
- Joseph V. Simone Award for Excellence in Quality and Safety in the Care of Patients with Cancer, American Society of Clinical Oncology (2018)
- President, American Society of Clinical Oncology (2009-10)
- The Ellen Stovall Award for Leadership in Patient-Centered Care, National Coalition for Cancer Survivorship (2016)
Administrative Appointments
- Medical Director, University of Michigan Comprehensive Cancer Center (2003 - 2010)
- Medical Director, Stanford Cancer Center (2010 - 2015)
- Medical Director for Quality, Stanford Cancer Institute (2015 - 2022)
- President, Wilshire Oncology Medical Group, Inc. (1996 - 2003)
Publications
-
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349)
Blayney, D. W., LeBlanc, M. L., Grogan, T., GAYNOR, E. R., Chapman, R. A., Spiridonidis, C. H., … Fisher, R. I. (2003). Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349). JOURNAL OF CLINICAL ONCOLOGY, 21(13), 2466–2473. -
The registry case finding engine: An automated tool to identify cancer cases from unstructured, free-text pathology reports and clinical notes.
Hanauer, D. A., Miela, G., Chinnaiyan, A. M., Chang, A. E., & Blayney, D. W. (2007). The registry case finding engine: An automated tool to identify cancer cases from unstructured, free-text pathology reports and clinical notes. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 205(5), 690–697. -
Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer
Hassett, M. J., Hughes, M. E., Niland, J. C., Edge, S. B., Theriault, R. L., Wong, Y.-N., … Weeks, J. C. (2008). Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY, 26(34), 5553–5560. -
Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center
Knight, J. S., Tsodikov, A., Cibrik, D. M., Ross, C. W., Kaminski, M. S., & Blayney, D. W. (2009). Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center. JOURNAL OF CLINICAL ONCOLOGY, 27(20), 3354–3362. -
Implementation of the Quality Oncology Practice Initiative at a University Comprehensive Cancer Center
Blayney, D. W., McNiff, K., Hanauer, D., Miela, G., Markstrom, D., & Neuss, M. (2009). Implementation of the Quality Oncology Practice Initiative at a University Comprehensive Cancer Center. JOURNAL OF CLINICAL ONCOLOGY, 27(23), 3802–3807. -
Enhancing Quality Through Innovation: American Society of Clinical Oncology Presidential Address 2010
Blayney, D. W. (2010). Enhancing Quality Through Innovation: American Society of Clinical Oncology Presidential Address 2010. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4283–4288. -
Expansion of cancer care and control in countries of low and middle income: a call to action
Farmer, P., Frenk, J., Knaul, F. M., Shulman, L. N., Alleyne, G., Armstrong, L., … Seffrin, J. R. (2010). Expansion of cancer care and control in countries of low and middle income: a call to action. LANCET, 376(9747), 1186–1193. -
Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites.
Baer, A. R., Kelly, C. A., Bruinooge, S. S., Runowicz, C. D., & Blayney, D. W. (2010). Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites. Journal of Oncology Practice / American Society of Clinical Oncology, 6(3), 114–117. -
Defining Quality: QOPI Is a Start.
Blayney, D. W. (2006). Defining Quality: QOPI Is a Start. Journal of Oncology Practice / American Society of Clinical Oncology, 2(5), 203-? -
Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?
Wong, Y.-N., Ottesen, R. A., Hughes, M. E., Niland, J. C., Theriault, R., Edge, S. B., … Weeks, J. C. (2011). Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence? ONCOLOGIST, 16(5), 559–565. -
Partnering with payers for success: quality oncology practice initiative, blue cross blue shield of michigan, and the michigan oncology quality consortium.
Blayney, D. W., Stella, P. J., Ruane, T., Martin, J., Lavasseur, B., Leyden, T., & Malloy, M. (2009). Partnering with payers for success: quality oncology practice initiative, blue cross blue shield of michigan, and the michigan oncology quality consortium. Journal of Oncology Practice / American Society of Clinical Oncology, 5(6), 281–284. -
Institutional Variation in the Surgical Treatment of Breast Cancer A Study of the NCCN
Greenberg, C. C., Lipsitz, S. R., Hughes, M. E., Edge, S. B., Theriault, R., Wilson, J. L., … Weeks, J. C. (2011). Institutional Variation in the Surgical Treatment of Breast Cancer A Study of the NCCN. ANNALS OF SURGERY, 254(2), 339–345. -
The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers
Brewster, A. M., Etzel, C., Zhou, R., Wong, Y., Edge, S., Blayney, D. W., … Theriault, R. L. (2011). The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers. BREAST CANCER RESEARCH AND TREATMENT, 130(3), 897–904. -
Myeloid Growth Factors
Crawford, J., Allen, J., Armitage, J., Blayney, D. W., Cataland, S. R., Heaney, M. L., … Westmoreland, M. (2011). Myeloid Growth Factors. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(8), 914-? -
The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy
Kleinman, L., Benjamin, K., Viswanathan, H., Mattera, M. S., Bosserman, L., Blayney, D. W., & Revicki, D. A. (2012). The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy. QUALITY OF LIFE RESEARCH, 21(7), 1255–1266. -
Commentary: six years of trends in oncology practice data.
Blayney, D. W. (2011). Commentary: six years of trends in oncology practice data. Journal of Oncology Practice / American Society of Clinical Oncology, 7(5), 291–293. -
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database
LaCasce, A. S., Vandergrift, J. L., Rodriguez, M. A., Abel, G. A., Crosby, A. L., Czuczman, M. S., … Friedberg, J. W. (2012). Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. BLOOD, 119(9), 2093–2099. -
Michigan Oncology Practices Showed Varying Adherence Rates To Practice Guidelines, But Quality Interventions Improved Care
Blayney, D. W., Severson, J., Martin, C. J., Kadlubek, P., Ruane, T., & Harrison, K. (2012). Michigan Oncology Practices Showed Varying Adherence Rates To Practice Guidelines, But Quality Interventions Improved Care. HEALTH AFFAIRS, 31(4), 718–28. -
American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology
Schnipper, L. E., Smith, T. J., Raghavan, D., Blayney, D. W., Ganz, P. A., Mulvey, T. M., & Wollins, D. S. (2012). American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology. JOURNAL OF CLINICAL ONCOLOGY, 30(14), 1715–1724. -
Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network
Lin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y.-N., … Weeks, J. C. (2012). Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network. CANCER, 118(22), 5463–5472. -
The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer
Partridge, A. H., Hughes, M. E., Ottesen, R. A., Wong, Y.-N., Edge, S. B., Theriault, R. L., … Tamimi, R. M. (2012). The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer. ONCOLOGIST, 17(6), 775–782. -
Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer
Hassett, M. J., Silver, S. M., Hughes, M. E., Blayney, D. W., Edge, S. B., Herman, J. G., … Weeks, J. C. (2012). Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2218–2226. -
Time to diagnosis and breast cancer stage by race/ethnicity
Warner, E. T., Tamimi, R. M., Hughes, M. E., Ottesen, R. A., Wong, Y.-N., Edge, S. B., … Partridge, A. H. (2012). Time to diagnosis and breast cancer stage by race/ethnicity. BREAST CANCER RESEARCH AND TREATMENT, 136(3), 813–821. -
Tumor Boards (Team Huddles) Aren't Enough to Reach the Goal
Blayney, D. W. (2013). Tumor Boards (Team Huddles) Aren't Enough to Reach the Goal. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 105(2), 82–84. -
Measuring the Improving Quality of Outpatient Care in Medical Oncology Practices in the United States
Neuss, M. N., Malin, J. L., Chan, S., Kadlubek, P. J., Adams, J. L., Jacobson, J. O., … Simone, J. V. (2013). Measuring the Improving Quality of Outpatient Care in Medical Oncology Practices in the United States. JOURNAL OF CLINICAL ONCOLOGY, 31(11), 1471–1477. -
DECREASING RISK OF LEUKEMIA WITH PROLONGED FOLLOW-UP AFTER CHEMOTHERAPY AND RADIOTHERAPY FOR HODGKINS-DISEASE
Blayney, D. W., Longo, D. L., Young, R. C., Greene, M. H., Hubbard, S. M., POSTAL, M. G., … DeVita, V. T. (1987). DECREASING RISK OF LEUKEMIA WITH PROLONGED FOLLOW-UP AFTER CHEMOTHERAPY AND RADIOTHERAPY FOR HODGKINS-DISEASE. NEW ENGLAND JOURNAL OF MEDICINE, 316(12), 710–714. -
THE HUMAN T-CELL LEUKEMIA LYMPHOMA VIRUS ASSOCIATED WITH AMERICAN ADULT T-CELL LEUKEMIA LYMPHOMA
Blayney, D. W., Jaffe, E. S., Blattner, W. A., Cossman, J., ROBERTGUROFF, M., Longo, D. L., … Gallo, R. C. (1983). THE HUMAN T-CELL LEUKEMIA LYMPHOMA VIRUS ASSOCIATED WITH AMERICAN ADULT T-CELL LEUKEMIA LYMPHOMA. BLOOD, 62(2), 401–405. -
THE HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS IN THE SOUTHEASTERN UNITED-STATES
Blayney, D. W., Blattner, W. A., ROBERTGUROFF, M., Jaffe, E. S., Fisher, R. I., Bunn, P. A., … Gallo, R. C. (1983). THE HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS IN THE SOUTHEASTERN UNITED-STATES. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 250(8), 1048–1052. -
THE HUMAN T-CELL LEUKEMIA LYMPHOMA VIRUS, LYMPHOMA, LYTIC BONE-LESIONS, AND HYPERCALCEMIA
Blayney, D. W., Jaffe, E. S., Fisher, R. I., Schechter, G. P., Cossman, J., ROBERTGUROFF, M., … Gallo, R. C. (1983). THE HUMAN T-CELL LEUKEMIA LYMPHOMA VIRUS, LYMPHOMA, LYTIC BONE-LESIONS, AND HYPERCALCEMIA. ANNALS OF INTERNAL MEDICINE, 98(2), 144–151. -
Computerized prescriber order entry implementation in a physician assistant-managed hematology and oncology inpatient service: effects on workflow and task switching.
Hanauer, D. A., Zheng, K., Commiskey, E. L., Duck, M. G., Choi, S. W., & Blayney, D. W. (2013). Computerized prescriber order entry implementation in a physician assistant-managed hematology and oncology inpatient service: effects on workflow and task switching. Journal of Oncology Practice / American Society of Clinical Oncology, 9(4), e103–14. -
Measuring and improving quality of care in an academic medical center.
Blayney, D. W. (2013). Measuring and improving quality of care in an academic medical center. Journal of Oncology Practice / American Society of Clinical Oncology, 9(3), 138–141. -
Myeloid Growth Factors
Crawford, J., Armitage, J., Balducci, L., Becker, P. S., Blayney, D. W., Cataland, S. R., … Ho, M. (2013). Myeloid Growth Factors. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(10), 1266–90. -
American society of clinical oncology 2013 top five list in oncology.
Schnipper, L. E., Lyman, G. H., Blayney, D. W., Hoverman, J. R., Raghavan, D., Wollins, D. S., & Schilsky, R. L. (2013). American society of clinical oncology 2013 top five list in oncology. Journal of Clinical Oncology , 31(34), 4362–70. -
Breast Cancer Treatment Across Health Care Systems
Kurian, A. W., Mitani, A., Desai, M., Yu, P. P., Seto, T., Weber, S. C., … Das, A. K. (2014). Breast Cancer Treatment Across Health Care Systems. CANCER, 120(1), 103–11. -
Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research.
Kurian, A. W., Mitani, A., Desai, M., Yu, P. P., Seto, T., Weber, S. C., … Das, A. K. (2014). Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research. Cancer, 120(1), 103–11. -
Transforming cancer care: are transdisciplinary approaches using design-thinking, engineering, and business methodologies needed to improve value in cancer care delivery?
Patel, M. I., Moore, D., Blayney, D. W., & Milstein, A. (2014). Transforming cancer care: are transdisciplinary approaches using design-thinking, engineering, and business methodologies needed to improve value in cancer care delivery? Journal of Oncology Practice / American Society of Clinical Oncology, 10(2), e51–4. -
ASCO's Quality Care Symposium (November 1-2, 2013) Abstracts
Kuznetsov, J. L., Bailey, K., Bombach, P. K., Carmichael, S., Chen, X., Herberg, M. L., … Blayney, D. W. (2013). ASCO's Quality Care Symposium (November 1-2, 2013) Abstracts. JOURNAL OF CLINICAL ONCOLOGY, 31(31). -
Reply to L.k. Griffeth et Al and j.e. Battley et Al.
Schnipper, L. E., Schilsky, R. L., Hoverman, J. R., Raghavan, D., Lyman, G. H., Wollins, D. S., & Blayney, D. W. (2014). Reply to L.k. Griffeth et Al and j.e. Battley et Al. Journal of Clinical Oncology , 32(25), 2812–13. -
Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy.
Knight, J. S., Blayney, D. W., & Somers, E. C. (2014). Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy. Lupus Science & Medicine, 1(1). -
Development and Future of the American Society of Clinical Oncology's Quality Oncology Practice Initiative
Blayney, D. W., McNiff, K., Eisenberg, P. D., Gilmore, T., Jacobsen, P. B., Jacobson, J. O., … Simone, J. (2014). Development and Future of the American Society of Clinical Oncology's Quality Oncology Practice Initiative. JOURNAL OF CLINICAL ONCOLOGY, 32(35), 3907–U174. -
Administration of oral chemotherapy: results from three rounds of the quality oncology practice initiative.
Zerillo, J. A., Pham, T. H., Kadlubek, P., Severson, J. A., Mackler, E., Jacobson, J. O., & Blayney, D. W. (2015). Administration of oral chemotherapy: results from three rounds of the quality oncology practice initiative. Journal of Oncology Practice / American Society of Clinical Oncology, 11(2), e255–62. -
Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond.
Hiatt, R. A., Tai, C. G., Blayney, D. W., Deapen, D., Hogarth, M., Kizer, K. W., … Schrag, D. (2015). Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond. Journal of the National Cancer Institute, 107(5). -
Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer
Kesler, S. R., Watson, C. L., & Blayney, D. W. (2015). Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. NEUROBIOLOGY OF AGING, 36(8), 2429–42. -
American society of clinical oncology third quality care symposium.
Earle, C. C., Jacobson, J. O., & Blayney, D. W. (2015). American society of clinical oncology third quality care symposium. Journal of Oncology Practice / American Society of Clinical Oncology, 11(3), 167-? -
Transforming data from information to quality improvement: a panel discussion with electronic health record vendors.
Blayney, D. W. (2015). Transforming data from information to quality improvement: a panel discussion with electronic health record vendors. Journal of Oncology Practice / American Society of Clinical Oncology, 11(3), 174–175. -
Detecting unplanned care from clinician notes in electronic health records.
Tamang, S., Patel, M. I., Blayney, D. W., Kuznetsov, J., Finlayson, S. G., Vetteth, Y., & Shah, N. (2015). Detecting unplanned care from clinician notes in electronic health records. Journal of Oncology Practice / American Society of Clinical Oncology, 11(3), e313–9. -
Do Wise Choices Translate Into Cost Savings and Improved Outcomes?
Blayney, D. W. (2015). Do Wise Choices Translate Into Cost Savings and Improved Outcomes? Journal of Oncology Practice / American Society of Clinical Oncology, 11(4), 344–345. -
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Warner, E. T., Tamimi, R. M., Hughes, M. E., Ottesen, R. A., Wong, Y.-N., Edge, S. B., … Partridge, A. H. (2015). Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. Journal of Clinical Oncology , 33(20), 2254–61. -
A NEW SUBTYPE OF HUMAN T-CELL LEUKEMIA-VIRUS (HTLV-II) ASSOCIATED WITH A T-CELL VARIANT OF HAIRY-CELL LEUKEMIA
Kalyanaraman, V. S., SARNGADHARAN, M. G., ROBERTGUROFF, M., Miyoshi, I., Blayney, D., Golde, D., & Gallo, R. C. (1982). A NEW SUBTYPE OF HUMAN T-CELL LEUKEMIA-VIRUS (HTLV-II) ASSOCIATED WITH A T-CELL VARIANT OF HAIRY-CELL LEUKEMIA. SCIENCE, 218(4572), 571–573. -
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., … American Society of Clinical Oncology. (2015). American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology , 33(23), 2563–77. -
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., … Schilsky, R. L. (2015). American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology , 33(23), 2563–2577. -
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Warner, E. T., Tamimi, R. M., Hughes, M. E., Ottesen, R. A., Wong, Y.-N., Edge, S. B., … Partridge, A. H. (2015). Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. Journal of Clinical Oncology , 33(20), 2254–2261. -
Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors.
Kesler, S. R., & Blayney, D. W. (2016). Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors. JAMA Oncology, 2(2), 185–92. -
New Paradigms for Patient-Centered Outcomes Research in Electronic Medical Records: An Example of Detecting Urinary Incontinence Following Prostatectomy.
Hernandez-Boussard, T., Tamang, S., Blayney, D., Brooks, J., & Shah, N. (2016). New Paradigms for Patient-Centered Outcomes Research in Electronic Medical Records: An Example of Detecting Urinary Incontinence Following Prostatectomy. EGEMS (Washington, DC), 4(3), 1231-? -
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., … Schilsky, R. L. (2016). Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology , 34(24), 2925–34. -
Are Patients With Thoracic Malignancies at Risk for Uncontrolled Symptoms?
Patel, M. I., Williams, D. C., Wohlforth, C., Fisher, G., Wakelee, H. A., & Blayney, D. W. (2015). Are Patients With Thoracic Malignancies at Risk for Uncontrolled Symptoms? Journal of Oncology Practice / American Society of Clinical Oncology, 11(1), e98–e102. -
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.
Partridge, A. H., Hughes, M. E., Warner, E. T., Ottesen, R. A., Wong, Y.-N., Edge, S. B., … Tamimi, R. M. (2016). Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. Journal of Clinical Oncology , 34(27), 3308–14. -
Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy.
Mackler, E., Petersen, L., Severson, J., Blayney, D. W., Benitez, L. L., Early, C. R., … Griggs, J. J. (2017). Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy. Journal of Oncology Practice, JOP2016018390-? -
The Appropriate Provision of Primary versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives
Gidwani, R., Nevedal, A., Patel, M., Blayney, D. W., Timko, C., Ramchandran, K., … Asch, S. M. (2017). The Appropriate Provision of Primary versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives. JOURNAL OF PALLIATIVE MEDICINE, 20(4), 395–403. -
Redesigning Cancer Care Delivery: Views From Patients and Caregivers.
Patel, M. I., Periyakoil, V. S., Blayney, D. W., Moore, D., Nevedal, A., Asch, S., … Coker, T. R. (2017). Redesigning Cancer Care Delivery: Views From Patients and Caregivers. Journal of Oncology Practice, 13(4), e291–e302. -
Disrupted brain network functional dynamics and hyper-correlation of structural and functional connectome topology in patients with breast cancer prior to treatment
Kesler, S. R., Adams, M., Packer, M., Rao, V., Henneghan, A. M., Blayney, D. W., & Palesh, O. (2017). Disrupted brain network functional dynamics and hyper-correlation of structural and functional connectome topology in patients with breast cancer prior to treatment. BRAIN AND BEHAVIOR, 7(3). -
Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center
Porter, J. B. (2017). Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center, 13(8), e673–e682. -
Achieving the triple aim in cancer care through a tri-part research collaboration.
Patel, M. I., Ramirez, D., Nguyen, A., Hagan, C., Asch, S. M., Agajanian, H. H., … Blayney, D. W. (2016). Achieving the triple aim in cancer care through a tri-part research collaboration. JOURNAL OF CLINICAL ONCOLOGY, 34(7). -
PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., … Blayney, D. (2013). PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER. JOURNAL OF THORACIC ONCOLOGY, 8, S1324. -
Mining Electronic Health Records to Extract Patient-Centered Outcomes Following Prostate Cancer Treatment.
Hernandez-Boussard, T., Kourdis, P. D., Seto, T., Ferrari, M., Blayney, D. W., Rubin, D., & Brooks, J. D. (2017). Mining Electronic Health Records to Extract Patient-Centered Outcomes Following Prostate Cancer Treatment. AMIA ... Annual Symposium Proceedings. AMIA Symposium, 2017, 876–82. -
Predicting Long-Term Cognitive Outcome Following Breast Cancer with Pre-Treatment Resting State fMRI and Random Forest Machine Learning
Kesler, S. R., Rao, A., Blayney, D. W., Oakley-Girvan, I. A., Karuturi, M., & Palesh, O. (2017). Predicting Long-Term Cognitive Outcome Following Breast Cancer with Pre-Treatment Resting State fMRI and Random Forest Machine Learning. FRONTIERS IN HUMAN NEUROSCIENCE, 11, 555. -
Critical Lessons From High-Value Oncology Practices
Blayney, D. W., Simon, M. K., Podtschaske, B., Ramsey, S., Shyu, M., Lindquist, C., & Milstein, A. (2018). Critical Lessons From High-Value Oncology Practices. JAMA ONCOLOGY, 4(2), 164–71. -
Efficacy of Medicaid for Patients With Cancer in California
Blayney, D. W. (2018). Efficacy of Medicaid for Patients With Cancer in California. JAMA ONCOLOGY, 4(3), 323–25. -
Myeloid Growth Factors, Version 2.2017 Clinical Practice Guidelines in Oncology
Crawford, J., Becker, P. S., Armitage, J. O., Blayney, D. W., Chavez, J., Curtin, P., … Pluchino, L. (2017). Myeloid Growth Factors, Version 2.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(12), 1520-+. -
Developing a non-hormonal treatment for vaginal dryness for breast cancer survivors: A pilot study of a therapeutic ultrasound device
David, S. M. L., Rockweiler, H., Krone, R., Middelton, S., & Blayney, D. (2018). Developing a non-hormonal treatment for vaginal dryness for breast cancer survivors: A pilot study of a therapeutic ultrasound device. CANCER RESEARCH, 78(4). -
ARE PATIENTS' NEEDS BEING MET AFTER-HOURS? AN EVALUATION OF PHONE CALLS MADE AFTER HOURS FOR PATIENTS WITH THORACIC MALIGNANCIES.
Patel, M. I., Williams, D., Wohlforth, C., Fisher, G. A., Blayney, D., & Wakelee, H. A. (2013). ARE PATIENTS' NEEDS BEING MET AFTER-HOURS? AN EVALUATION OF PHONE CALLS MADE AFTER HOURS FOR PATIENTS WITH THORACIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, S709. -
Are patients' needs being met after hours? An evaluation of phone calls made after hours for patients with thoracic malignancies.
Patel, M. I., Moore, D., Milstein, A., Wakelee, H. A., & Blayney, D. W. (2013). Are patients' needs being met after hours? An evaluation of phone calls made after hours for patients with thoracic malignancies. JOURNAL OF CLINICAL ONCOLOGY, 31(31). -
Are needs of stakeholders in cancer care being met? A novel approch to assessing needs to improve value in cancer care
Patel, M. I., Moore, D., Randolph, S., Wakelee, H. A., Blayney, D. W., & Milstein, A. (2013). Are needs of stakeholders in cancer care being met? A novel approch to assessing needs to improve value in cancer care. JOURNAL OF CLINICAL ONCOLOGY, 31(15). -
Architecture and Implementation of a Clinical Research Data Warehouse for Prostate Cancer.
Seneviratne, M. G., Seto, T., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2018). Architecture and Implementation of a Clinical Research Data Warehouse for Prostate Cancer. EGEMS (Washington, DC), 6(1), 13. -
Oncologists' Views on Using Value to Guide Cancer Treatment Decisions
Gidwani-Marszowski, R., Nevedal, A. L., Blayney, D. W., Patel, M., Kelly, P. A., Timko, C., … Asch, S. M. (2018). Oncologists' Views on Using Value to Guide Cancer Treatment Decisions. VALUE IN HEALTH, 21(8), 931–37. -
Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer.
Seneviratne, M. G., Bozkurt, S., Patel, M. I., Seto, T., Brooks, J. D., Blayney, D. W., … Hernandez-Boussard, T. (2018). Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. Cancer. -
Better, Safer, Cheaper: Joseph V. Simone Award and Lecture.
Blayney, D. W. (2018). Better, Safer, Cheaper: Joseph V. Simone Award and Lecture. Journal of Oncology Practice, 14(12), 763–66. -
Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients
Blayney, D., Ogenstad, S., Shi, Y., Zhang, Q., Du, L., Huang, L., & Mohanlal, R. (2018). Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients. JOURNAL OF THORACIC ONCOLOGY, 13(10), S461. -
Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition
Blayney, D. W., Ette, E., Ogenstad, S., Shi, Y., Du, L., Lloyd, K., … Mohanlal, R. (2018). Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition. BLOOD, 132. -
Plinabulin (Plin), a novel non-G-CSF molecule for the revention of chemotherapy-induced neutropenia (CIN), has the potential to positively impact tumor micro environment
Blayney, D., Ogenstad, S., Shi, Y.-K., Zhang, Q., Du, L., Huang, L., & Mohanlal, R. (2018). Plinabulin (Plin), a novel non-G-CSF molecule for the revention of chemotherapy-induced neutropenia (CIN), has the potential to positively impact tumor micro environment. ANNALS OF ONCOLOGY, 29. -
Can measuring quality lead to improvement? Evidence from international participants of ASCO's quality oncology practice initiative (QOPIV (R)) during 2015-2017
Jahanzeb, M., Gilmore, T., Roach, A., Grubbs, S. S., Blayney, D., Hamm, J., … Hendricks, C. (2018). Can measuring quality lead to improvement? Evidence from international participants of ASCO's quality oncology practice initiative (QOPIV (R)) during 2015-2017. ANNALS OF ONCOLOGY, 29, 571. -
Survivorship care plan: Use of the 'Oncology History' (OncHx) feature of the Epic electronic health record (EHR).
Bugos, K., Foran, J., Petree, J. M., Sabati, K. P., Bruels, M., Cook, M., … Blayney, D. W. (2017). Survivorship care plan: Use of the 'Oncology History' (OncHx) feature of the Epic electronic health record (EHR). JOURNAL OF CLINICAL ONCOLOGY, 35(5). -
Computing the cost of care per day of breast cancer survivor care.
Blayney, D. W., Lindquist, C., Seto, T., Nhat Minh Hoang, & Kurian, A. W. (2018). Computing the cost of care per day of breast cancer survivor care. JOURNAL OF CLINICAL ONCOLOGY, 36(7). -
Patient reported symptom severity in cancer survivors.
Bugos, K., Foran, J., Sabati, K. P., Valdez, A., Petree, J. M., Wellman, C., & Blayney, D. W. (2017). Patient reported symptom severity in cancer survivors. JOURNAL OF CLINICAL ONCOLOGY, 35(5). -
Practice-based evidence for factors associated with urinary incontinence following prostate cancer care.
Li, K., Magnani, C. J., Bozkurt, S., Seto, T., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2018). Practice-based evidence for factors associated with urinary incontinence following prostate cancer care. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Therapeutic Ultrasound as a Novel, Non-hormonal Treatment of Vulvo-vaginal Atrophy: A Pilot Phase II Study
MacLaughlan, S., Rockweiler, H., Krone, R., Middleton, S., & Blayney, D. (2017). Therapeutic Ultrasound as a Novel, Non-hormonal Treatment of Vulvo-vaginal Atrophy: A Pilot Phase II Study. GYNECOLOGIC ONCOLOGY, 147(1), 235. -
Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation Report
Neuss, M., Rocque, G., Zuckerman, D., Chiang, A., Katta, S., Wollins, D., … Edge, S. (2017). Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation Report. JOURNAL OF ONCOLOGY PRACTICE, 13(2), 135-+. -
Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy
Blayney, D. W., Bazhenova, L., Lloyd, G. K., Huang, L., & Mohanlal, R. (2016). Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy. BLOOD, 128(22). -
Where Does Dynamic Value Assessment Fit Into Our Role as Agents Advising Our Patients With Cancer?
Blayney, D. W. (2016). Where Does Dynamic Value Assessment Fit Into Our Role as Agents Advising Our Patients With Cancer? JOURNAL OF ONCOLOGY PRACTICE, 12(12), 1211–13. -
Using technology to improve quality metric adherence
Jacobsen, P. B., Gaguski, M., Thomas, K. A., Hathaway, A., Halilova, K. I., Stricker, C. T., … Rocque, G. B. (2016). Using technology to improve quality metric adherence. JOURNAL OF CLINICAL ONCOLOGY, 34(7). -
Choosing Wisely in oncology: Are we ready for value-based care?
Rocque, G. B., Blayney, D., Jahanzeb, M., Kadlubek, P., Knape, A., Markham, M. J., … Evans, T. L. (2016). Choosing Wisely in oncology: Are we ready for value-based care? JOURNAL OF CLINICAL ONCOLOGY, 34(7). -
Using a web analytic tool to evaluate Pathways program engagement in 36 Michigan oncology practices.
Seung, A. H., Justus, R., Klamerus, J. F. A., & Blayney, D. W. (2016). Using a web analytic tool to evaluate Pathways program engagement in 36 Michigan oncology practices. JOURNAL OF CLINICAL ONCOLOGY, 34(7). -
Using technology to improve patient-provider communication and delivery of quality care.
Rocque, G. B., Hathaway, A., Halilova, K. I., Gaguski, M., Thomas, K. A., Stricker, C. T., … Blayney, D. W. (2016). Using technology to improve patient-provider communication and delivery of quality care. JOURNAL OF CLINICAL ONCOLOGY, 34(7). -
Is screening enough? Implications of a pilot utilizing standard screening criteria for early palliative referral
Ramchandran, K., Winget, M., Tribett, E. L., Anderson, B., Morris, A., & Blayney, D. W. (2015). Is screening enough? Implications of a pilot utilizing standard screening criteria for early palliative referral. JOURNAL OF CLINICAL ONCOLOGY, 33(29). -
From PRO screening to improved wellness: A nurse-led intervention
Morris, A., Tribett, E. L., Tun, S., Winget, M., Blayney, D. W., & Ramchandran, K. (2015). From PRO screening to improved wellness: A nurse-led intervention. JOURNAL OF CLINICAL ONCOLOGY, 33(29). -
Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype.
Partridge, A. H., Hughes, M. E., Ottesen, R., Wong, Y.-N., Edge, S. B., Theriault, R. L., … Tamimi, R. M. (2011). Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype. CANCER RESEARCH, 71. -
Mobile cognitive assessment battery (MCAB) for assessment of cancer-related cognitive changes.
Kesler, S., & Blayney, D. W. (2014). Mobile cognitive assessment battery (MCAB) for assessment of cancer-related cognitive changes. JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
Oral chemotherapy performance indicators: Early results from three rounds of Quality Oncology Practice Initiative (QOPI) data
Zerillo, J. A., Trang Pham, Kadlubek, P., Severson, J. A., Mackler, E., Jacobson, J. O., & Blayney, D. W. (2014). Oral chemotherapy performance indicators: Early results from three rounds of Quality Oncology Practice Initiative (QOPI) data. JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
Survivorship care plan: Use of the "Oncology History" (OncHx) feature of the Epic electronic health record (EHR).
Bugos, K., Mishra, P., Bruels, M., Laport, G., Herring, B., Pose, K., … Blayney, D. W. (2014). Survivorship care plan: Use of the "Oncology History" (OncHx) feature of the Epic electronic health record (EHR). JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
Association of high symptom burden with oral oncolytic agents
Severson, J. A., Mackler, E. R., Marini, B., & Blayney, D. W. (2015). Association of high symptom burden with oral oncolytic agents. JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
Choosing wisely: Treatment recommendations from 36 Michigan Oncology Clinical Treatment Pathways practices
Seung, A. H., Hamel, L. M., Stella, P. J., Klamerus, J. F. A., & Blayney, D. W. (2015). Choosing wisely: Treatment recommendations from 36 Michigan Oncology Clinical Treatment Pathways practices. JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
The use of a palliative care tool in a community private practice
Mahmood, T., Shock, H., Severson, J., & Blayney, D. W. (2012). The use of a palliative care tool in a community private practice. JOURNAL OF CLINICAL ONCOLOGY, 30(34). -
Measuring the improving quality of outpatient care in medical oncology practices in the United States
Neuss, M. N., Malin, J., Chan, S., Kadlubek, P., Adams, J. L., Joseph, J., … Simone, J. V. (2012). Measuring the improving quality of outpatient care in medical oncology practices in the United States. JOURNAL OF CLINICAL ONCOLOGY, 30(34). -
Real-time extraction of breast cancer treatment process and outcome measures from an EPIC electronic health record (EHR)
Kuznetsov, J. L., Bailey, K., Bombach, P. K., Carmichael, S., Chen, X., Herberg, M. L., … Blayney, D. W. (2013). Real-time extraction of breast cancer treatment process and outcome measures from an EPIC electronic health record (EHR). JOURNAL OF CLINICAL ONCOLOGY, 31(31). -
Models That Work: Incorporating Quality Principles in Different Clinical Settings
Krzyzanowska, M. K., Blayney, D. W., Bosserman, L. D., & Sullivan, T. J. (2013). Models That Work: Incorporating Quality Principles in Different Clinical Settings. JOURNAL OF ONCOLOGY PRACTICE, 9(3), 135–37. -
Introduction to the ASCO Quality Care Symposium
Blayney, D. W., Stovall, E. L., & Earle, C. C. (2013). Introduction to the ASCO Quality Care Symposium. JOURNAL OF ONCOLOGY PRACTICE, 9(3), 113. -
A randomized clinical trial of the combination of Plinabulin (Plin) plus Pegfilgrastim (Peg) versus (vs) Peg alone for TAC (docetaxel, doxorubicin, cyclophosphamide) induced Neutropenia (CIN)
Blayney, D., Ogenstad, S., Shi, Y., Zhang, Q., Sun, T., Du, L., … Mohanlal, R. (2019). A randomized clinical trial of the combination of Plinabulin (Plin) plus Pegfilgrastim (Peg) versus (vs) Peg alone for TAC (docetaxel, doxorubicin, cyclophosphamide) induced Neutropenia (CIN). BREAST, 44, S21. -
Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement: A Structured Review
Gori, D., Dulal, R., Blayney, D. W., Brooks, J. D., Fantini, M. P., McDonald, K. M., & Hernandez-Boussard, T. (2019). Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement: A Structured Review. JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY, 45(3), 217–26. -
A natural language processing algorithm to measure quality prostate cancer care.
Hernandez-Boussard, T., Kourdis, P., Dulal, R., Ferrari, M., Henry, S., Seto, T., … Brooks, J. D. (2017). A natural language processing algorithm to measure quality prostate cancer care. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Comparison of Orthogonal NLP Methods for Clinical Phenotyping and Assessment of Bone Scan Utilization among Prostate Cancer Patients.
Coquet, J., Bozkurt, S., Kan, K. M., Ferrari, M. K., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2019). Comparison of Orthogonal NLP Methods for Clinical Phenotyping and Assessment of Bone Scan Utilization among Prostate Cancer Patients. Journal of Biomedical Informatics, 103184. -
Choosing Wisely in Oncology: Are We Ready For Value-Based Care?
Rocque, G., Blayney, D. W., Jahanzeb, M., Knape, A., Markham, M. J., Pham, T., … Evans, T. (2017). Choosing Wisely in Oncology: Are We Ready For Value-Based Care? Journal of Oncology Practice, 13(11), e935–e943. -
Improving care with portfolio of physician-led cancer quality measures at an academic center
Porter, J., Smith, A. S., Winget, M., Rosenthal, E. L., Seshadri, S. B., Vetteth, Y., … Blayney, D. W. (2017). Improving care with portfolio of physician-led cancer quality measures at an academic center. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
"DID YOU FEEL THE EARTH SHAKE?" AN ONLINE CANCER COMMUNITY INTERPRETS RESULTS OF A PRACTICE-CHANGING TRIAL
Hall, E., Schapira, L., Zeiger, R., Blayney, D. W., & Trivedi, R. (2019). "DID YOU FEEL THE EARTH SHAKE?" AN ONLINE CANCER COMMUNITY INTERPRETS RESULTS OF A PRACTICE-CHANGING TRIAL. ANNALS OF BEHAVIORAL MEDICINE, 53, S39. -
PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.
Magnani, C. J., Li, K., Seto, T., McDonald, K. M., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2019). PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes. Journal of the National Comprehensive Cancer Network : JNCCN, 17(7), 795–803. -
Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing? A single-centre retrospective study.
Bozkurt, S., Kan, K. M., Ferrari, M. K., Rubin, D. L., Blayney, D. W., Hernandez-Boussard, T., & Brooks, J. D. (2019). Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing? A single-centre retrospective study. BMJ Open, 9(7), e027182. -
REDUCTION IN PATIENT REPORTED BONE PAIN WITH PLINABULIN VS PEGFILGRASTIM IN NON SMALL CELL LUNG CANCER PATIENTS TREATED FOR THE PREVENTION OF DOCETAXEL-INDUCED NEUTROPENIA
Blayney, D., Mitchell, D., Lelorier, Y., Huang, L., & Mohanlal, R. (2019). REDUCTION IN PATIENT REPORTED BONE PAIN WITH PLINABULIN VS PEGFILGRASTIM IN NON SMALL CELL LUNG CANCER PATIENTS TREATED FOR THE PREVENTION OF DOCETAXEL-INDUCED NEUTROPENIA. VALUE IN HEALTH, 22, S109. -
Distribution of Global Health Measures From Routinely Collected PROMIS Surveys in Patients With Breast Cancer or Prostate Cancer
Seneviratne, M. G., Bozkurt, S., Patel, M., Seto, T., Brooks, J. D., Blayney, D. W., … Hernandez-Boussard, T. (2019). Distribution of Global Health Measures From Routinely Collected PROMIS Surveys in Patients With Breast Cancer or Prostate Cancer. CANCER, 125(6), 943–51. -
Better, Safer, Cheaper: Joseph V. Simone Award and Lecture
Blayney, D. W. (2018). Better, Safer, Cheaper: Joseph V. Simone Award and Lecture. JOURNAL OF ONCOLOGY PRACTICE, 14(12), 763-+. -
Increasing Epic staging module adherence in an academic cancer center
Porter, J., Smith, A. S., Cook, M., Boncato, K., Bruels, M., Duda-Stavlund, E., & Blayney, D. W. (2017). Increasing Epic staging module adherence in an academic cancer center. JOURNAL OF CLINICAL ONCOLOGY, 35(8). -
Quality, clinician and information technology (IT) partnership for metric reporting.
Smith, A. S., Porter, J., Badwe, A., Kiamanesh, E. F., & Blayney, D. W. (2017). Quality, clinician and information technology (IT) partnership for metric reporting. JOURNAL OF CLINICAL ONCOLOGY, 35(8). -
What role should value play in cancer care?
Gidwani, R., Blayney, D. W., Patel, M. I., Asch, S. M., Kelly, A., & Nevedal, A. (2016). What role should value play in cancer care? JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
The ideal interface between oncology and palliative care: Views from the field.
Gidwani, R., Blayney, D. W., Patel, M. I., Asch, S. M., Kelly, P. A., & Nevedal, A. (2016). The ideal interface between oncology and palliative care: Views from the field. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Machine Learning Approaches for Extracting Stage from Pathology Reports in Prostate Cancer.
Lenain, R., Seneviratne, M. G., Bozkurt, S., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2019). Machine Learning Approaches for Extracting Stage from Pathology Reports in Prostate Cancer. Studies in Health Technology and Informatics, 264, 1522–23. -
Extracting Patient-Centered Outcomes from Clinical Notes in Electronic Health Records: Assessment of Urinary Incontinence After Radical Prostatectomy.
Gori, D., Banerjee, I., Chung, B. I., Ferrari, M., Rucci, P., Blayney, D. W., … Hernandez-Boussard, T. (2019). Extracting Patient-Centered Outcomes from Clinical Notes in Electronic Health Records: Assessment of Urinary Incontinence After Radical Prostatectomy. EGEMS (Washington, DC), 7(1), 43. -
Comparison of pegfilgrastim (Peg), plinabulin (Plin), and the combination for chemotherapy (Chemo) induced neutropenia (CIN) prevention: Rationale for the combination.
Blayney, D. W., Ogenstad, S., Shi, Y., Zhang, Q., Feng, J., Sun, T., … Mohanlal, R. (2019). Comparison of pegfilgrastim (Peg), plinabulin (Plin), and the combination for chemotherapy (Chemo) induced neutropenia (CIN) prevention: Rationale for the combination. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Real-world efficacy of bone modifying agents (BMAs) in patients with breast cancer (BC) treated in an academic health system: Use of the "green button.
Karimi, Y., Gombar, S., Dean, L., Hansen, J., Callahan, A., Jung, K., … Blayney, D. W. (2019). Real-world efficacy of bone modifying agents (BMAs) in patients with breast cancer (BC) treated in an academic health system: Use of the "green button. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
A phase II trial with the combination of plinabulin (plin) pegfilgrastim (peg): Evaluation of the reversal of peg's immune-suppressive potential by the addition of plin to peg.
Blayney, D. W., Ogenstad, S., Shi, Y., Feng, J. F., Zhang, Q., Sun, T., … Mohanlal, R. (2019). A phase II trial with the combination of plinabulin (plin) pegfilgrastim (peg): Evaluation of the reversal of peg's immune-suppressive potential by the addition of plin to peg. JOURNAL OF CLINICAL ONCOLOGY, 37(8). -
Quality of Life in NSCLC Patients Treated with Docetaxel and Either Plinabulin or Pegfilgrastim for Prevention of Neutropenia
Blayney, D., Mitchell, D., Lelorier, Y., Huang, L., & Mohanlal, R. (2019). Quality of Life in NSCLC Patients Treated with Docetaxel and Either Plinabulin or Pegfilgrastim for Prevention of Neutropenia. JOURNAL OF THORACIC ONCOLOGY, 14(10), S359. -
The effect of increasing doses of pegfilgrastim (Peg) on thrombocytopenia (T) in breast cancer (BC) patients (pts) receiving taxotere (Doc), doxorubicin, cyclophosphamide (TAC) and plinabulin (Plin)
Blayney, D. W., Bondarenko, I., Shi, Y., Ogenstad, S., Du, L., Huang, L., & Mohanlal, R. (2019). The effect of increasing doses of pegfilgrastim (Peg) on thrombocytopenia (T) in breast cancer (BC) patients (pts) receiving taxotere (Doc), doxorubicin, cyclophosphamide (TAC) and plinabulin (Plin). ANNALS OF ONCOLOGY, 30, 737. -
Predicting Patient Reported Outcomes of Cognitive Function Using Connectome-Based Predictive Modeling in Breast Cancer.
Henneghan, A. M., Gibbons, C., Harrison, R. A., Edwards, M. L., Rao, V., Blayney, D. W., … Kesler, S. R. (2019). Predicting Patient Reported Outcomes of Cognitive Function Using Connectome-Based Predictive Modeling in Breast Cancer. Brain Topography. -
Cortical Brain Age from Pre-treatment to Post-chemotherapy in Patients with Breast Cancer.
Henneghan, A., Rao, V., Harrison, R. A., Karuturi, M., Blayney, D. W., Palesh, O., & Kesler, S. R. (2020). Cortical Brain Age from Pre-treatment to Post-chemotherapy in Patients with Breast Cancer. Neurotoxicity Research. -
Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer
Li, K., Banerjee, I., Magnani, C. J., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2020). Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer. RESEARCH AND REPORTS IN UROLOGY, 12, 7–14. -
Leveraging Digital Data to Inform and Improve Quality Cancer Care.
Hernandez-Boussard, T., Blayney, D. W., & Brooks, J. D. (2020). Leveraging Digital Data to Inform and Improve Quality Cancer Care. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. -
Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer.
Li, K., Banerjee, I., Magnani, C. J., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2020). Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer. Research and Reports in Urology, 12, 7–14. -
Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients
Coquet, J., Bozkurt, S., Kan, K. M., Ferrari, M. K., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2019). Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients. JOURNAL OF BIOMEDICAL INFORMATICS, 94. -
Computing the Cost of Care Per Day for Patients With Metastatic NETs
Gupta, D., Kapphahn, K., Qin, F. F., Hornbacker, K., Henry, S., Wood, D., … Kunz, P. (2020). Computing the Cost of Care Per Day for Patients With Metastatic NETs. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification.
Blayney, D. W., Albdelhafeez, N., Jazieh, A. R., Pinto, C. F., Udrea, A., Roach, A., … Siegel, R. (2020). International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification. JCO Global Oncology, 6, 697–703. -
Plinabulin (Plin), a novel non-G-CSF molecule for the revention of chemotherapy-induced neutropenia (CIN), has the potential to positively impact tumor micro environment.
Blayney, D., Ogenstad, S., Shi, Y.-K., Zhang, Q., Du, L., Huang, L., & Mohanlal, R. (2018). Plinabulin (Plin), a novel non-G-CSF molecule for the revention of chemotherapy-induced neutropenia (CIN), has the potential to positively impact tumor micro environment. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29 Suppl 8, viii604. -
Can measuring quality lead to improvement? Evidence from international participants of ASCO's quality oncology practice initiative (QOPI) during 2015-2017.
Jahanzeb, M., Gilmore, T., Roach, A., Grubbs, S. S., Blayney, D., Hamm, J., … Hendricks, C. (2018). Can measuring quality lead to improvement? Evidence from international participants of ASCO's quality oncology practice initiative (QOPI) during 2015-2017. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29 Suppl 8, viii571. -
Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (phi) 2 results from a head-to-head comparison with Pegfilgrastim (Peg).
Blayney, D. W., Shi, Y., Bondarenko, I., Zhang, Q., Kovalenko, N. V., Feng, J., … Mohanlal, R. W. (2018). Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (phi) 2 results from a head-to-head comparison with Pegfilgrastim (Peg). JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Impact of mortality reviews on supportive care utilization, end-of-life care, and inpatient mortality.
Karimi, Y., Divi, V., Srinivas, S., Smith, A. S., Hansen, J., Tokareva, I., … Blayney, D. W. (2019). Impact of mortality reviews on supportive care utilization, end-of-life care, and inpatient mortality. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Blayney, D. W., Zhang, Q., Feng, J., Zhao, Y., Bondarenko, I., Vynnychenko, I., … Shi, Y.-K. (2020). Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncology. -
Association between patient-initiated emails and overall 2-year survival in cancer patients undergoing chemotherapy: Evidence from the real-world setting.
Coquet, J., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2020). Association between patient-initiated emails and overall 2-year survival in cancer patients undergoing chemotherapy: Evidence from the real-world setting. Cancer Medicine. -
Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model.
Roy, M., Neal, J. W., Bugos, K., Sharp, C., Falconer, P., Rosenthal, E. L., … Ramchandran, K. (2020). Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Four distinct patient-reported outcome (PRO) trajectories in longitudinal responses collected before, during, and after chemotherapy.
Blayney, D. W., Azad, A., Yilmaz, M., Bozkurt, S., Brooks, J. D., & Hernandez-Boussard, T. (2020). Four distinct patient-reported outcome (PRO) trajectories in longitudinal responses collected before, during, and after chemotherapy. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site.
Karimi, Y., Blayney, D. W., Kurian, A. W., Rubin, D., & Banerjee, I. (2020). Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Plinabulin (Plin) is a more favorable option for the prevention of chemotherapy induced neutropenia (CIN) than pegfilgrastim (Peg) during the COVID-19 pandemic
Blayney, D., Mohanlal, R., & Huang, L. (2020). Plinabulin (Plin) is a more favorable option for the prevention of chemotherapy induced neutropenia (CIN) than pegfilgrastim (Peg) during the COVID-19 pandemic. ANNALS OF ONCOLOGY, 31, S1008. -
Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance.
Magnani, C. J., Bievre, N., Baker, L. C., Brooks, J. D., Blayney, D. W., & Hernandez-Boussard, T. (2021). Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance. European Urology Open Science, 23, 20–29. -
Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis
Mohanlal, R., Blayney, D. W., & Huang, L. (2019). Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis. BLOOD, 134. -
A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) plus Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)
Blayney, D. W., Huang, L., & Mohanlal, R. (2019). A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) plus Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin). BLOOD, 134. -
Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)
Blayney, D. W., Huang, L., & Mohanlal, R. (2019). Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN). BLOOD, 134. -
Benchmark Method for Cost Computations across Healthcare Systems: Cost of Care per Patient per Day in Breast Cancer Care
Blayney, D. W., Seto, T., Hoang, N., Lindquist, C., & Kurian, A. W. (2021). Benchmark Method for Cost Computations across Healthcare Systems: Cost of Care per Patient per Day in Breast Cancer Care. JCO Oncology Practice. -
Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (OIs).
Karimi, Y., Purington, N., Liu, M., Kurian, A. W., Sledge, G. W., & Blayney, D. W. (2020). Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (OIs). JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
A comparison of CD34+mobilization effects of standard dose pegfilgrastim (Peg) versus low-dose peg combined with plinabulin (Plin).
Blayney, D. W., Huang, L., & Mohanlal, R. W. (2020). A comparison of CD34+mobilization effects of standard dose pegfilgrastim (Peg) versus low-dose peg combined with plinabulin (Plin). JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Protective-2 (bpi-2358-106): A confirmatory trial to demonstrate superiority of the plinabulin plus pegfilgrastim (plin/peg) combination versus standard of care pegfilgrastim for the prevention of chemotherapy-induced neutropenia (cin) in breast cancer (bc) patients (pts)
Blayney, D. W., Huang, L., & Mohanlal, R. W. (2021). Protective-2 (bpi-2358-106): A confirmatory trial to demonstrate superiority of the plinabulin plus pegfilgrastim (plin/peg) combination versus standard of care pegfilgrastim for the prevention of chemotherapy-induced neutropenia (cin) in breast cancer (bc) patients (pts). CANCER RESEARCH, 81(4). -
Plinabulin and pegfilgrastim (Plin plus Peg) versus peg monotherapy (Peg) after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain
Blayney, D. W., Ginn, G., Huang, L., & Mohanlal, R. W. (2021). Plinabulin and pegfilgrastim (Plin plus Peg) versus peg monotherapy (Peg) after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain. CANCER RESEARCH, 81(4). -
Differential efficacy of pegfilgrastim (Peg) in patients (pts) with breast cancer (BC) versus other cancer types for the prevention of docetaxel (Doc) chemotherapy-induced neutropenia (CIN)
Blayney, D. W., Ginn, G., Huang, L., & Mohanlal, R. (2021). Differential efficacy of pegfilgrastim (Peg) in patients (pts) with breast cancer (BC) versus other cancer types for the prevention of docetaxel (Doc) chemotherapy-induced neutropenia (CIN). CANCER RESEARCH, 81(4). -
Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model.
Neal, J. W., Roy, M., Bugos, K., Sharp, C., Galatin, P. S., Falconer, P., … Ramchandran, K. (2021). Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model. JCO Oncology Practice, OP2000473. -
Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer.
Roy, M., Purington, N., Liu, M., Blayney, D. W., Kurian, A. W., & Schapira, L. (2021). Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer. JCO Oncology Practice, OP2001093. -
Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data.
Karimi, Y. H., Blayney, D. W., Kurian, A. W., Shen, J., Yamashita, R., Rubin, D., & Banerjee, I. (2021). Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data. JCO Clinical Cancer Informatics, 5, 469–78. -
Treatment and Monitoring Variability in US Metastatic Breast Cancer Care.
Caswell-Jin, J. L., Callahan, A., Purington, N., Han, S. S., Itakura, H., John, E. M., … Kurian, A. W. (2021). Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO Clinical Cancer Informatics, 5, 600–614. -
EFFICACY OF BRIEF BEHAVIORAL THERAPY FOR HEADACHE MANAGEMENT IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY
Woldeamanuel, Y., Blayney, D. W., Jo, B., Fisher, S., Benedict, C., Kesler, S., … Palesh, O. (2021). EFFICACY OF BRIEF BEHAVIORAL THERAPY FOR HEADACHE MANAGEMENT IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY. ANNALS OF BEHAVIORAL MEDICINE. OXFORD UNIV PRESS INC. -
Diverse patient trajectories during cytotoxic chemotherapy: Capturing longitudinal patient-reported outcomes.
Azad, A. D., Yilmaz, M., Bozkurt, S., Brooks, J. D., Blayney, D. W., & Hernandez-Boussard, T. (2021). Diverse patient trajectories during cytotoxic chemotherapy: Capturing longitudinal patient-reported outcomes. Cancer Medicine. -
Pioneering Cancer Quality: Lessons From Dr Joe Simone.
Blayney, D. W. (2021). Pioneering Cancer Quality: Lessons From Dr Joe Simone. JCO Oncology Practice, OP2100358. -
Headache outcomes of a sleep behavioral intervention in breast cancer survivors: Secondary analysis of a randomized clinical trial.
Woldeamanuel, Y. W., Blayney, D. W., Jo, B., Fisher, S. E., Benedict, C., Oakley-Girvan, I., … Palesh, O. (2021). Headache outcomes of a sleep behavioral intervention in breast cancer survivors: Secondary analysis of a randomized clinical trial. Cancer. -
Health management via telemedicine: Learning from the COVID-19 experience.
Sun, R., Blayney, D. W., & Hernandez-Boussard, T. (2021). Health management via telemedicine: Learning from the COVID-19 experience. Journal of the American Medical Informatics Association : JAMIA. -
PHARMACOKINETICS OF HIGH-DOSE FOLINIC ACID (DL-CF) ADMINISTERED BY CONTINUOUS INTRAVENOUS (IV) INFUSION
NEWMAN, E., DOROSHOW, J., BERTRAND, M., BURGESON, P., VILLACORTE, D., BLAYNEY, D., … STAPLES, R. (1985). PHARMACOKINETICS OF HIGH-DOSE FOLINIC ACID (DL-CF) ADMINISTERED BY CONTINUOUS INTRAVENOUS (IV) INFUSION. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
LEUKEMIA AFTER TREATMENT OF OVARIAN-CANCER OR HODGKINS-DISEASE
BLAYNEY, D. W., & LONGO, D. L. (1990). LEUKEMIA AFTER TREATMENT OF OVARIAN-CANCER OR HODGKINS-DISEASE. NEW ENGLAND JOURNAL OF MEDICINE, 322(25), 1818. -
Eighty-five cases of lymphoma in a solid organ transplant (SOT) population: Risk, treatment, and histologic subtype
Knight, J. S., Tsodikov, A., Cibrik, D. M., Ross, C. W., Kaminski, M. S., & Blayney, D. W. (2007). Eighty-five cases of lymphoma in a solid organ transplant (SOT) population: Risk, treatment, and histologic subtype. BLOOD. AMER SOC HEMATOLOGY. -
Implementation of the quality oncology practice initiative in a hospital-based, University Comprehensive Cancer Center.
Blayney, D. W., Miela, G., Markstrom, D., Marlin, C. J., Hanauer, D., McNiff, K., … Hayes, D. F. (2006). Implementation of the quality oncology practice initiative in a hospital-based, University Comprehensive Cancer Center. BREAST CANCER RESEARCH AND TREATMENT. SPRINGER. -
Apoptosis and Bcl-2 expression in circulating tumor cells from women being treated for metastatic breast cancer.
Smerage, J. B., Doyle, G., Budd, G. T., Wicha, M. S., Schott, A. F., Blayney, D. W., … Hayes, D. F. (2006). Apoptosis and Bcl-2 expression in circulating tumor cells from women being treated for metastatic breast cancer. BREAST CANCER RESEARCH AND TREATMENT. SPRINGER. -
Apoptosis and Bcl-2 expression in circulating tumor cells (CTC) from women being treated for metastatic breast cancer
Smerage, J. B., Doyl, G. V., Budd, T., Schott, A. F., Blayney, D. W., Wicha, M. S., … Hayes, D. F. (2007). Apoptosis and Bcl-2 expression in circulating tumor cells (CTC) from women being treated for metastatic breast cancer. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS. WICHTIG EDITORE. -
The Registry Case Finding Engine (CaFE): An automated approach for cancer patient identification from unstructured, free-text pathology reports.
Hanauer, D. A., Chinnaiyan, A. M., Miela, G., & Blayney, D. W. (2006). The Registry Case Finding Engine (CaFE): An automated approach for cancer patient identification from unstructured, free-text pathology reports. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
From the editor's desk
From the editor's desk. (2006). MATRIX BIOLOGY, 25(1), 1–2. -
Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in Non-Hodgkin's Lymphoma
Gregory, S. A., Blayney, D. W., Vadhan-Raj, S., Tomita, D. K., Rossi, G., & Mirtsching, B. (2004). Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in Non-Hodgkin's Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Efficacy of darbepoetin alfa in chemotherapy-induced anemia in gastrointestinal cancers.
Blayney, D., Vadhan-Raj, S., Tomita, D., Rossi, G., & Mirtsching, B. (2005). Efficacy of darbepoetin alfa in chemotherapy-induced anemia in gastrointestinal cancers. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA).
Vadhan-Raj, S., Mirtsching, B., Gregory, S. A., Hong, J., Fessen, M., Yao, B., … Blayney, D. (2004). Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
The relationships between FACT-Fatigue (FACT-F) scores and physical function (PF) in patients (pts) with chemotherapy-induced anemia treated with darbepoetin alfa (DA).
Cella, D., Evans, W., Wallace, J., Kallich, J., Blayney, D., & Vadhan-Raj, S. (2004). The relationships between FACT-Fatigue (FACT-F) scores and physical function (PF) in patients (pts) with chemotherapy-induced anemia treated with darbepoetin alfa (DA). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Chemotherapy use for hormone receptor-positive, node-negative breast cancer
Hassett, M. J., Hughes, M. E., Niland, J. C., Edge, S. B., Theriault, R. L., Wong, Y., … Weeks, J. C. (2007). Chemotherapy use for hormone receptor-positive, node-negative breast cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
The detection of apoptosis and Bcl-2 expression in circulating tumor cells (CTCs) from women being treated for metastatic breast cancer
Smerage, J. B., Doyle, G. V., Budd, G. T., Schott, A. F., Blayney, D. W., Wicha, M. S., … Hayes, D. F. (2006). The detection of apoptosis and Bcl-2 expression in circulating tumor cells (CTCs) from women being treated for metastatic breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
CHANGES IN PROSTATE SPECIFIC ANTIGEN SCREENING AND PROSTATE CANCER DIAGNOSIS AFTER GUIDELINE CHANGES
Magnani, C. J., Li, K., Seto, T., McDonald, K. M., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2018). CHANGES IN PROSTATE SPECIFIC ANTIGEN SCREENING AND PROSTATE CANCER DIAGNOSIS AFTER GUIDELINE CHANGES. JOURNAL OF UROLOGY. ELSEVIER SCIENCE INC. -
From the Editor's Desk
Blayney, D. W. (2005). From the Editor's Desk. JOURNAL OF ONCOLOGY PRACTICE, 1(2). -
Every-2-week darbepoetin alfa improves hemoglobin in anemic patients with cancer undergoing chemotherapy: A stratified analysis by tumor type.
Blayney, D., Fesen, M., Mirtsching, B. C., Katz, D., Tomita, D., & Colowick, A. (2003). Every-2-week darbepoetin alfa improves hemoglobin in anemic patients with cancer undergoing chemotherapy: A stratified analysis by tumor type. BLOOD. AMER SOC HEMATOLOGY. -
An investigation into the impact of weight on the efficacy of darbepoetin alfa administered as a fixed dose of 200 mcg every 2 weeks (Q2W).
Heatherington, A., Gabrilove, J., Blayney, D., Tomita, D., & Rossi, G. (2003). An investigation into the impact of weight on the efficacy of darbepoetin alfa administered as a fixed dose of 200 mcg every 2 weeks (Q2W). BLOOD. AMER SOC HEMATOLOGY. -
Darbepoetin alfa 3.0 mcg/kg every 2 weeks improves hemoglobin and quality of life in a subset of breast cancer patients in a community-based trial of patients with chemotherapy-induced anemia.
Blayney, D. W., Vadhan-Raj, S., Mirtsching, B. C., Tomita, D., & Colowick, A. (2003). Darbepoetin alfa 3.0 mcg/kg every 2 weeks improves hemoglobin and quality of life in a subset of breast cancer patients in a community-based trial of patients with chemotherapy-induced anemia. BREAST CANCER RESEARCH AND TREATMENT. KLUWER ACADEMIC PUBL. -
Improved access to tobacco cessation services for cancer patients using a statewide collaborative approach.
Severson, J. A., Baca, H., Blayney, D. W., Brown, K., Galiyas, G., Minasian, M., … Warren, G. W. (2014). Improved access to tobacco cessation services for cancer patients using a statewide collaborative approach. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Using a statewide collaborative approach to improve tobacco cessation referral rates for cancer patients
Severson, J., Baca, H., Blayney, D., Brown, K., Galiyas, G., Minasian, M., … Warren, G. (2014). Using a statewide collaborative approach to improve tobacco cessation referral rates for cancer patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Using a statewide collaborative approach to improve tobacco cessation referral rates for cancer patients
Severson, J. A., Baca, H., Blayney, D. W., Brown, K., Galiyas, G., Minasian, M., … Warren, G. W. (2013). Using a statewide collaborative approach to improve tobacco cessation referral rates for cancer patients. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
ANTIGENICALLY DEFINED SUBGROUPS OF LYMPHOBLASTIC LYMPHOMA - THEIR RELATIONSHIP TO CLINICAL PRESENTATION AND BIOLOGIC BEHAVIOR
SHEIBANI, K., NATHWANI, B. N., WINBERG, C. D., BURKE, J. S., SWARTZ, W. G., BLAYNEY, D., … RAPPAPORT, H. (1987). ANTIGENICALLY DEFINED SUBGROUPS OF LYMPHOBLASTIC LYMPHOMA - THEIR RELATIONSHIP TO CLINICAL PRESENTATION AND BIOLOGIC BEHAVIOR. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP. -
DISTRIBUTION OF LYMPHOCYTES WITH INTERLEUKIN 2 RECEPTORS (TACANTIGENS) IN REACTIVE LYMPHOPROLIFERATIVE PROCESSES, HODGKINS-DISEASE, AND NON-HODGKINS-LYMPHOMAS - AN IMMUNOHISTOLOGIC STUDY OF 300 CASES
SHEIBANI, K., WINBERG, C., VANDEVELDE, S., BLAYNEY, D., & RAPPAPORT, H. (1987). DISTRIBUTION OF LYMPHOCYTES WITH INTERLEUKIN 2 RECEPTORS (TACANTIGENS) IN REACTIVE LYMPHOPROLIFERATIVE PROCESSES, HODGKINS-DISEASE, AND NON-HODGKINS-LYMPHOMAS - AN IMMUNOHISTOLOGIC STUDY OF 300 CASES. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP. -
Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service.
Hanauer, D. A., Zheng, K., Choi, S. W., Beasley, R., Schumacher, J., Duck, M., & Blayney, D. W. (2010). Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Use of a 21-gene reverse transcriptase-polymerase chain reaction (RT-PCR) assay to guide therapy in 14 Michigan Breast Oncology Quality Initiative (MiBOQI) sites
Silver, S. M., Ali, H. Y., Blayney, D. W., Caughran, J., Herman, J. G., Pettinga, J. E., … Vandergrift, J. L. (2010). Use of a 21-gene reverse transcriptase-polymerase chain reaction (RT-PCR) assay to guide therapy in 14 Michigan Breast Oncology Quality Initiative (MiBOQI) sites. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
The effect of age on delay in diagnosis and stage of breast cancer
Partridge, A. H., Hughes, M. E., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., … Tamimi, R. M. (2010). The effect of age on delay in diagnosis and stage of breast cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy.
Hassett, M. J., Niland, J. C., Hughes, M. E., Theriault, R. L., Blayney, D. W., Wong, Y., … Weeks, J. C. (2010). Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Continued use of trastuzumab (TRZ) beyond disease progression in the National Comprehensive Cancer Network (NCCN)
Wong, Y., Ottesen, R., Niland, J., Hughes, M., Theriault, R., Edge, S., … Weeks, J. C. (2008). Continued use of trastuzumab (TRZ) beyond disease progression in the National Comprehensive Cancer Network (NCCN). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Measuring quality with the Quality Oncology Practice Initiative (QOPI) at a university comprehensive cancer center
Blayney, D. W., Miela, G., Markstrom, D., Hanauer, D., McNiff, K., & Neuss, M. (2007). Measuring quality with the Quality Oncology Practice Initiative (QOPI) at a university comprehensive cancer center. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Introduction of computerized provider order entry (CPOE) and time impact in an inpatient hematology/oncology service: Serial time and motion studies
Hanauer, D. A., Beasley, R. W., Schumacher, J., Duck, M. G., & Blayney, D. W. (2009). Introduction of computerized provider order entry (CPOE) and time impact in an inpatient hematology/oncology service: Serial time and motion studies. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
The impact of obesity on adherence to the National Comprehensive Cancer Network (NCCN) guidelines recommending chemotherapy for patients with operable breast cancer
Brewster, A. M., Etzel, C., Zhou, R., Wong, Y., Edge, S. B., Blayney, D. W., … Theriault, R. L. (2009). The impact of obesity on adherence to the National Comprehensive Cancer Network (NCCN) guidelines recommending chemotherapy for patients with operable breast cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Quality of breast cancer care in NCCN centers as assessed by the ASCO/NCCN quality measures: Overall performance and reasons for nonconcordance
Hughes, M. E., Ottesen, R., Niland, J. C., Edge, S. B., Theriault, R. L., Wilson, J., … Weeks, J. C. (2009). Quality of breast cancer care in NCCN centers as assessed by the ASCO/NCCN quality measures: Overall performance and reasons for nonconcordance. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN)
Lin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y., … Weeks, J. C. (2009). Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database
Abel, G. A., Vanderplas, A., Friedberg, J. W., Niland, J., Rodriguez, M. A., Czuczman, M. S., … LaCasce, A. S. (2009). Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. BLOOD. AMER SOC HEMATOLOGY. -
R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project
LaCasce, A., Vandergrift, J. L., Rodriguez, M. A., Crosby, A. L., Lepisto, E. M., Czuczman, M. S., … Friedberg, J. W. (2009). R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project. BLOOD. AMER SOC HEMATOLOGY. -
Making the Choice Between Academic Oncology and Community Practice: The Big Picture and Details About Each Career
Desch, C. E., & Blayney, D. W. (2006). Making the Choice Between Academic Oncology and Community Practice: The Big Picture and Details About Each Career. JOURNAL OF ONCOLOGY PRACTICE, 2(3), 132–136. -
Who Will Do the Work? What Work Will They Do?
Blayney, D. W. (2007). Who Will Do the Work? What Work Will They Do? JOURNAL OF ONCOLOGY PRACTICE, 3(2), 53. -
TUMOR TRAPPING OF 5-FLUOROURACIL - INVIVO F-19 NMR SPECTROSCOPIC PHARMACOKINETICS IN TUMOR-BEARING HUMANS AND RABBITS
WOLF, W., PRESANT, C. A., SERVIS, K. L., ELTAHTAWY, A., ALBRIGHT, M. J., BARKER, P. B., … SHANI, J. (1990). TUMOR TRAPPING OF 5-FLUOROURACIL - INVIVO F-19 NMR SPECTROSCOPIC PHARMACOKINETICS IN TUMOR-BEARING HUMANS AND RABBITS. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 87(1), 492–496. -
Optimal use of antiemetics in the outpatient setting - The Grunberg article reviewed
Blayney, D. W. (2002). Optimal use of antiemetics in the outpatient setting - The Grunberg article reviewed. ONCOLOGY-NEW YORK, 16(10), 1407–1408. -
Dose-intense CHOPx2 therapy of intermediate grade lymphoma - A phase II study of the southwest oncology group (SWOG).
Blayney, D. W., LeBlanc, M. L., & Fisher, R. I. (2001). Dose-intense CHOPx2 therapy of intermediate grade lymphoma - A phase II study of the southwest oncology group (SWOG). BLOOD. AMER SOC HEMATOLOGY. -
Development of the Anemia Impact Measure (AIM): A Disease-Specific Patient Reported outcome (PRO) Instrument to Measure Anemia Symptoms and Their Impact on Functioning in Cancer Patients Receiving Chemotherapy
Kleinman, L., Benjamin, K., Viswanathan, H., Mattera, M. S., Bosserman, L. D., Blayney, D. W., & Revicki, D. (2008). Development of the Anemia Impact Measure (AIM): A Disease-Specific Patient Reported outcome (PRO) Instrument to Measure Anemia Symptoms and Their Impact on Functioning in Cancer Patients Receiving Chemotherapy. BLOOD. AMER SOC HEMATOLOGY. -
DECREASING RISK OF LEUKEMIA WITH PROLONGED FOLLOW-UP AFTER CHEMOTHERAPY AND RADIOTHERAPY FOR HODGKINS-DISEASE - REPLY
BLAYNEY, D. W., DEVITA, V. T., YOUNG, R. C., GREENE, M. H., HUBBARD, S. M., POSTAL, M. G., … LONGO, D. L. (1987). DECREASING RISK OF LEUKEMIA WITH PROLONGED FOLLOW-UP AFTER CHEMOTHERAPY AND RADIOTHERAPY FOR HODGKINS-DISEASE - REPLY. NEW ENGLAND JOURNAL OF MEDICINE, 317(11), 708–709. -
RECOMBINANT INTERLEUKIN-2 (IL2) THERAPY PRODUCES AZOTEMIA, SODIUM RETENTION, HYPOALBUMINEMIA AND EDEMA
TEXTOR, S. C., MARGOLIN, K., BLAYNEY, D., & DOROSHOW, J. (1987). RECOMBINANT INTERLEUKIN-2 (IL2) THERAPY PRODUCES AZOTEMIA, SODIUM RETENTION, HYPOALBUMINEMIA AND EDEMA. KIDNEY INTERNATIONAL. BLACKWELL SCIENCE INC. -
SCREENING FOR HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS - REPLY
BLAYNEY, D. W. (1984). SCREENING FOR HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS - REPLY. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 251(12), 1555. -
EVIDENCE FOR HUMAN T-LEUKEMIA VIRUS DEFECTION IN PATIENTS WITH THE ACQUIRED IMMUNE-DEFICIENCY SYNDROME
GELMANN, E. P., BLAYNEY, D., ROBERTGUROFF, M., WONGSTAAL, F., & GALLO, R. C. (1983). EVIDENCE FOR HUMAN T-LEUKEMIA VIRUS DEFECTION IN PATIENTS WITH THE ACQUIRED IMMUNE-DEFICIENCY SYNDROME. CLINICAL RESEARCH. SLACK INC. -
ADULT T-CELL LYMPHOMA IN THE UNITED-STATES - A HIGH-GRADE NON-HODGKINS LYMPHOMA ASSOCIATED WITH HUMAN T-CELL LYMPHOMA VIRUS
BUNN, P., SCHECHTER, G., JAFFE, E., YOUNG, R., BLAYNEY, D., BLATTNER, W., … GALLO, R. (1983). ADULT T-CELL LYMPHOMA IN THE UNITED-STATES - A HIGH-GRADE NON-HODGKINS LYMPHOMA ASSOCIATED WITH HUMAN T-CELL LYMPHOMA VIRUS. CLINICAL RESEARCH. SLACK INC. -
THE HUMAN T-CELL LEUKEMIA LYMPHOMA VIRUS - TIS ASSOCIATION WITH DISEASE IN THE UNITED-STATES
JAFFE, E. S., BLAYNEY, D. W., BLATTNER, W., COSSMAN, J., ROBERTGUROFF, M., & GALLO, R. C. (1983). THE HUMAN T-CELL LEUKEMIA LYMPHOMA VIRUS - TIS ASSOCIATION WITH DISEASE IN THE UNITED-STATES. LABORATORY INVESTIGATION. WILLIAMS & WILKINS. -
EARLY DETECTION OF CISPLATIN RESISTANCE IN FRESH HUMAN CARCINOMA-CELLS BY INVITRO ENZYMATIC AMPLIFICATION ASSAY
KASHANISABET, M., ROSSI, J. J., LU, Y., CHEN, J., MIYACHI, H., MA, J. X., … SCANLON, K. J. (1988). EARLY DETECTION OF CISPLATIN RESISTANCE IN FRESH HUMAN CARCINOMA-CELLS BY INVITRO ENZYMATIC AMPLIFICATION ASSAY. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (Aredia(R)) infusion
Theriault, R. L., Horotbagyi, G. N., Porter, L., Blayney, D., Lipton, A., Gluck, S., … Reitsma, D. (1996). Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (Aredia(R)) infusion. BRITISH JOURNAL OF CANCER. STOCKTON PRESS. -
DOSE INTENSE MOPP/ABV WITH PROPHYLACTIC FILGRASTIM (G-CSF) TREATMENT OF ADVANCED HODGKINS-DISEASE (HD) - A PILOT-STUDY
BLAYNEY, D. W., BOSSERMAN, L. D., & VAKIL, M. (1994). DOSE INTENSE MOPP/ABV WITH PROPHYLACTIC FILGRASTIM (G-CSF) TREATMENT OF ADVANCED HODGKINS-DISEASE (HD) - A PILOT-STUDY. BLOOD. W B SAUNDERS CO. -
PHASE-II TRIAL OF 4'DEOXYDOXORUBICIN (DXDX) IN ADVANCED GASTRIC (GCA) AND PANCREATIC (PCA) CANCER
BLAYNEY, D. W., LEONG, L. A., GOLDBERG, D. A., MARGOLIN, K. A., CARR, B. I., AKMAN, S. A., & DOROSHOW, J. H. (1986). PHASE-II TRIAL OF 4'DEOXYDOXORUBICIN (DXDX) IN ADVANCED GASTRIC (GCA) AND PANCREATIC (PCA) CANCER. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
CASE 44-1981 - RADIATION-INDUCED PERICARDITIS
BLAYNEY, D. W., & LONGO, D. (1982). CASE 44-1981 - RADIATION-INDUCED PERICARDITIS. NEW ENGLAND JOURNAL OF MEDICINE, 306(9), 550. -
Impact of adding plinabulin to pegfilgrastim for the prevention of chemotherapy induced neutropenia (CIN) on patient quality of life (QoL)
Blayney, D., Le Lorier, Y., Mitchell, D., Huang, L., & Mohanlal, R. (2021). Impact of adding plinabulin to pegfilgrastim for the prevention of chemotherapy induced neutropenia (CIN) on patient quality of life (QoL). ANNALS OF ONCOLOGY. ELSEVIER. -
Prediction of febrile neutropenia (FN), hospitalization (Hosp) rates, and infection (Inf) rates in chemotherapy-induced neutropenia (CIN) patients (pts) treated with the plinabulin and pegfilgrastim combination (Plin plus Peg) using a meta-analysis (MA)-based tool
Ogenstad, S., Blayney, D., Huang, L., & Mohanlal, R. (2021). Prediction of febrile neutropenia (FN), hospitalization (Hosp) rates, and infection (Inf) rates in chemotherapy-induced neutropenia (CIN) patients (pts) treated with the plinabulin and pegfilgrastim combination (Plin plus Peg) using a meta-analysis (MA)-based tool. ANNALS OF ONCOLOGY. ELSEVIER. -
Severe neutropenia (grade 4, Gr4N) as a population-based predictor for adverse clinical outcome of chemotherapy induced neutropenia (CIN)
Mohanlal, R., Ogenstad, S., Huang, L., & Blayney, D. (2021). Severe neutropenia (grade 4, Gr4N) as a population-based predictor for adverse clinical outcome of chemotherapy induced neutropenia (CIN). ANNALS OF ONCOLOGY. ELSEVIER. -
Reply to Ritzwoller et al.
Karimi, Y. H., Kurian, A. W., Blayney, D. W., & Banerjee, I. (2021). Reply to Ritzwoller et al. JCO Clinical Cancer Informatics, 5, 1026–1027. -
Association of treatment type with patient-reported quality of life in cancer distress screening
Roy, M., Rosenthal, S., Shah, M. P., Khaki, A. R., Bozkurt, S., Seto, T., … Ramchandran, K. (2021). Association of treatment type with patient-reported quality of life in cancer distress screening. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Preventing 30-day readmissions for patients with cancer: A root-cause analysis
Shah, M. P., Tan, I., Garrigues, S. K., Hansen, J., Blayney, D. W., & Divi, V. (2021). Preventing 30-day readmissions for patients with cancer: A root-cause analysis. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care.
Blayney, D. W., Bariani, G., Das, D., Dawood, S., Gnant, M., De Guzman, R., … Hendricks, C. (2021). Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care. JCO Global Oncology, 7, 1513–1521. -
Machine Learning Applied to Electronic Health Records: Identification of Chemotherapy Patients at High Risk for Preventable Emergency Department Visits and Hospital Admissions.
Peterson, D. J., Ostberg, N. P., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2021). Machine Learning Applied to Electronic Health Records: Identification of Chemotherapy Patients at High Risk for Preventable Emergency Department Visits and Hospital Admissions. JCO Clinical Cancer Informatics, 5, 1106–1126. -
Identification of patients at high risk for preventable emergency department visits and inpatient admissions after starting chemotherapy: Machine learning applied to comprehensive electronic health record data.
Peterson, D. J., Ostberg, N. P., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2021). Identification of patients at high risk for preventable emergency department visits and inpatient admissions after starting chemotherapy: Machine learning applied to comprehensive electronic health record data. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).
Shi, Y., Blayney, D. W., Adamchuk, H., Zhang, Q., Du, L., Huang, L., & Mohanlal, R. (2021). Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1.
Blayney, D. W., Shi, Y., Bondarenko, I., Ogenstad, S., Zhang, Q., Du, L., … Mohanlal, R. (2021). Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.
Blayney, D. W., Shi, Y., Adamchuk, H., Feng, D., Zhang, Q., Du, L., … Mohanlal, R. (2021). Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of adding plinabulin to pegfilgrastim for the prevention of TAC chemotherapy (Chemo) induced neutropenia (CIN), on patient quality of life (QoL).
Mohanlal, R., Lelorier, Y., Mitchell, D., Huang, L., & Blayney, D. W. (2021). Impact of adding plinabulin to pegfilgrastim for the prevention of TAC chemotherapy (Chemo) induced neutropenia (CIN), on patient quality of life (QoL). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
Blayney, D. W., Mohanlal, R., Adamchuk, H., Kirtbaya, D. V., Chen, M., Du, L., … Zhang, Q. (1800). Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial. JAMA Network Open, 5(1), e2145446. -
Cancer Biosimilars-A Regulatory Success So Far, but Value Still to Be Determined.
Blayney, D. W., & Silver, S. M. (1800). Cancer Biosimilars-A Regulatory Success So Far, but Value Still to Be Determined. JAMA Oncology. -
Surgical solution for a paraneoplastic neurodegenerative disorder
Muhammad, H., Strayve, D. G., Narayan, R. R., Blayney, D. W., & Delitto, D. (2022). Surgical solution for a paraneoplastic neurodegenerative disorder. TRAUMA SURGERY & ACUTE CARE OPEN, 7(1). -
Surgical solution for a paraneoplastic neurodegenerative disorder.
Muhammad, H., Strayve, D. G., Narayan, R. R., Blayney, D. W., & Delitto, D. (2022). Surgical solution for a paraneoplastic neurodegenerative disorder. Trauma Surgery & Acute Care Open, 7(1), e000928. -
PREDICTIVE ENRICHMENT TO IDENTIFY RESPONSE TO SLEEP INTERVENTION IN CANCER SURVIVORS WITH HEADACHE - A PRECISION MEDICINE STUDY
Woldeamanuel, Y. W., Kushida, C. A., Kesler, S., Jo, B., Neri, E., Edwards, K. S., … Palesh, O. (2022). PREDICTIVE ENRICHMENT TO IDENTIFY RESPONSE TO SLEEP INTERVENTION IN CANCER SURVIVORS WITH HEADACHE - A PRECISION MEDICINE STUDY. ANNALS OF BEHAVIORAL MEDICINE. OXFORD UNIV PRESS INC. -
Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.
Blayney, D. W., & Schwartzberg, L. (2022). Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. Cancer Treatment Reviews, 109, 102427.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
- A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
- A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
- A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Practice Locations
Stanford Women's Cancer Center Palo Alto, CA
Palo Alto, CAStanford Women's Cancer Center
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereBreast Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CABreast Cancer Program in Palo Alto
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(90 reviews)
View More
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records